These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20019584)

  • 21. Androgen pathway resistance in prostate cancer and therapeutic implications.
    Maughan BL; Antonarakis ES
    Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.
    Foley C; Mitsiades N
    Horm Cancer; 2016 Apr; 7(2):84-103. PubMed ID: 26728473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
    Proverbs-Singh T; Feldman JL; Morris MJ; Autio KA; Traina TA
    Endocr Relat Cancer; 2015 Jun; 22(3):R87-R106. PubMed ID: 25722318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.
    Ryan CJ; Tindall DJ
    J Clin Oncol; 2011 Sep; 29(27):3651-8. PubMed ID: 21859989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Lee YH; Koo KC
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.
    Zarif JC; Miranti CK
    Cell Signal; 2016 May; 28(5):348-356. PubMed ID: 26829214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
    Mostaghel EA
    Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.